- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07560956
Quality of Life in Adults With Untreated Fabry Disease in Sweden (QoLUF) (QoLUF)
Quality of Life in Patients With Untreated Fabry Disease: A National Descriptive Study
Fabry disease is a rare, inherited condition that can affect multiple organs, including the heart, kidneys, and nervous system. Many people with Fabry disease live for a period of time without receiving disease-specific treatment, for example because treatment criteria have not yet been met. There is limited knowledge about how patients experience this period without treatment.
The purpose of this study is to improve understanding of how adults with Fabry disease who are not yet receiving disease-specific treatment experience their quality of life, their daily lives, and their contacts with health care services.
This is a national interview study in which participants will take part in one individual digital interview lasting approximately 45-60 minutes. During the interview, participants will be invited to describe their experiences in their own words, including symptoms, how the disease affects everyday life, psychological and emotional well-being, and experiences of follow-up and support from health care providers. Participants will also complete a short questionnaire with basic background information, such as age, education, and living situation.
By collecting and analyzing patients' own narratives, the study aims to identify needs, challenges, and support resources during the period without treatment. The results are expected to contribute to increased knowledge and to the development of more person-centered care for individuals living with Fabry disease.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Fabry disease is a rare X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, leading to deficiency of the enzyme alpha-galactosidase A. As a result, globotriaosylceramide (Gb3) accumulates in cells and tissues, causing progressive involvement of multiple organ systems, including the heart, kidneys, and central nervous system. Clinical manifestations and disease severity vary considerably between individuals and between sexes.
Disease-specific treatment options, such as enzyme replacement therapy and chaperone therapy, are available for Fabry disease. However, a subgroup of patients does not yet receive such treatment, either because established treatment criteria are not fulfilled or for other medical reasons. Patient experiences during this untreated period are insufficiently described in the current literature.
This study is a national, qualitative interview study aiming to describe how adult patients with Fabry disease who are not receiving disease-specific treatment experience their quality of life, disease situation, and interactions with health care services. The study is conducted in collaboration between the two Swedish national high-specialty care centers (National Highly Specialized Care, NHV) for Fabry disease at Sahlgrenska University Hospital in Gothenburg and Karolinska University Hospital in Stockholm.
Participants are recruited through the respective NHV clinics. After providing written informed consent, each participant takes part in a single individual semi-structured interview. Interviews are conducted digitally and last approximately 45-60 minutes. The interview guide covers topics such as symptoms and impact on daily life, psychological and emotional experiences, perceptions of health care follow-up and communication, involvement in care decisions, expectations regarding potential future treatment, and the impact of Fabry disease within the family.
Interviews are audio-recorded, transcribed verbatim, and de-identified prior to analysis. No information is obtained from medical records. In addition to the interview, participants complete a short questionnaire providing basic demographic information.
Data are analyzed using qualitative content analysis at both manifest and latent levels, applying an inductive approach. Through systematic analysis of participants' narratives, categories and overarching themes are developed to capture shared experiences, variations, and patterns in how individuals experience living with Fabry disease without current disease-specific treatment.
The study is expected to generate in-depth knowledge of patients' experiences during the untreated phase of Fabry disease and to inform the development of more person-centered follow-up and support within highly specialized care for rare diseases.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Dimitrios Chantzichristos, MD PhD
- Telefonnummer: +46 31 342 1000
- E-mail: dimitrios.chantzichristos@gu.se
Studiesteder
-
-
-
Gothenburg, Sverige, 413 45
- Sahlgrenska University Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Age 18 years or older
- Confirmed diagnosis of Fabry disease
- Followed at a National Highly Specialized Care (NHV) center for Fabry disease in Sweden (Sahlgrenska University Hospital or Karolinska University Hospital)
- Not currently receiving disease-specific treatment for Fabry disease (such as enzyme replacement therapy or chaperone therapy)
- Treatment may be considered in the future
- Ability to understand and speak Swedish
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Current or planned disease-specific treatment for Fabry disease
- Disease-specific treatment deemed permanently not indicated due to other medical conditions
- Actively declined an offered disease-specific treatment
- Inability to participate in a qualitative interview
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Adults with Fabry Disease Not Receiving Disease-Specific Treatment
This group includes adult patients diagnosed with Fabry disease who are not currently receiving disease-specific treatment (such as enzyme replacement therapy or chaperone therapy).
Participants are followed at national highly specialized care centers in Sweden and take part in a single qualitative interview to describe their experiences of living with Fabry disease without current treatment.
|
Non-interventional
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient-reported experiences of quality of life while living with untreated Fabry disease
Tidsramme: Single assessment during one qualitative interview (approximately 45-60 minutes)
|
Quality of life is explored through participant narratives obtained in a single semi-structured qualitative interview.
Participants describe how Fabry disease and the absence of disease-specific treatment affect their daily life, physical well-being, psychological and emotional experiences, social activities, and overall life situation.
|
Single assessment during one qualitative interview (approximately 45-60 minutes)
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Cerebrovaskulære lidelser
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Sygdomsegenskaber
- Metabolisme, medfødte fejl
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Lipidmetabolismeforstyrrelser
- Genetiske sygdomme, X-forbundet
- Lysosomale opbevaringssygdomme
- Hjernesygdomme, metaboliske, medfødte
- Hjernesygdomme, metaboliske
- Lipidmetabolisme, medfødte fejl
- Lysosomale opbevaringssygdomme, nervesystemet
- Cerebrale småkarsygdomme
- Sphingolipidoser
- Lipidoser
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Patologiske tilstande, tegn og symptomer
- Ernæringsmæssige og metaboliske sygdomme
- Sjældne sygdomme
- Fabrys sygdom
Andre undersøgelses-id-numre
- QoLUF 284843
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Fabrys sygdom
-
Shaare Zedek Medical CenterJohannes Gutenberg University MainzAfsluttet
-
GC Biopharma CorpHanmi Pharmaceutical Company LimitedRekrutteringFabry DisesaseForenede Stater, Argentina, Sydkorea
-
Lysosomal and Rare Disorders Research and Treatment...SanofiUkendtFabryForenede Stater
-
University Hospital, CaenUkendt
Kliniske forsøg med Qualitative Interview
-
Mayo ClinicIkke rekrutterer endnuSpontan koronararteriedissektionForenede Stater
-
Assistance Publique - Hôpitaux de ParisNational Cancer Institute, FranceAfsluttetKræft | Ældre | Etnografisk interview | Social repræsentation af at være ældre | Årsager til ikke-deltagelse i kliniske forsøg | Kvalitativ metodeFrankrig
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute on Alcohol... og andre samarbejdspartnereAfsluttet
-
University of ExeterUniversity of Nottingham; University of Bristol; National Institute for Health...AfsluttetDiabetes mellitusDet Forenede Kongerige
-
Beth Israel Deaconess Medical CenterAfsluttetDyspepsi | Halsbrand | Gastroøsofageal reflukssygdom (GERD)Forenede Stater
-
VA Office of Research and DevelopmentAfsluttetPost traumatisk stress syndromForenede Stater
-
J. Matthias WalzBrown UniversityAfsluttetMeddelelse | Ventilationsterapi; KomplikationerForenede Stater
-
Northwestern UniversityRegeneron PharmaceuticalsAfsluttetPsoriasis | Atopisk dermatitis | IktyoseForenede Stater
-
Direction Centrale du Service de Santé des ArméesRekruttering
-
I.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioAfsluttet